What is Amide Technologies?
Amide Technologies operates at the intersection of biotechnology and advanced chemical engineering. By leveraging its proprietary AFPS technology, the company addresses critical bottlenecks in the synthesis of complex peptides, which are essential for modern therapeutic discovery. Unlike conventional methods that often struggle with length and structural complexity, Amide provides a streamlined solution for synthesizing linear peptides of up to 120 amino acids. This capability is instrumental for pharmaceutical partners engaged in rapid design-build-test cycles, effectively reducing the time-to-market for novel therapeutic modalities. By bridging the gap between traditional chemical synthesis and biological expression, Amide has established itself as a vital infrastructure provider for the life sciences sector.
How much funding has Amide Technologies raised?
Amide Technologies has raised a total of $11.5M across 1 funding round:
Series A
$11.5M
Series A (2023): $11.5M with participation from The Engine
Key Investors in Amide Technologies
The Engine
The Engine is a venture capital firm founded by MIT that specializes in Tough Tech, focusing on transformative technologies that address fundamental challenges in human health and advanced infrastructure.
What's next for Amide Technologies?
With the recent capital injection, Amide Technologies is poised to transition from a specialized service provider to a cornerstone of the drug discovery ecosystem. The strategic roadmap focuses on expanding production capacity to accommodate larger, more complex molecular orders while maintaining the rapid turnaround times that define their market advantage. As the company scales, it will likely prioritize the integration of its synthesis platform into broader automated drug discovery workflows. This growth phase is expected to solidify Amide's role in supporting the development of next-generation therapeutics, potentially attracting further institutional backing as they continue to demonstrate the scalability and reliability of their AFPS technology in high-stakes clinical environments.
See full Amide Technologies company page
